(loo-TEE-shee-um … DOH-tuh-tayt )
This page contains brief information about lutetium Lu 177-dotatate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Lutetium Lu 177-dotatate is approved to treat:
- Gastroenteropancreatic neuroendocrine tumors. It is used in adults and children aged 12 years and older whose cancer is somatostatin receptor positive.
Lutetium Lu 177-dotatate is also being studied in the treatment of other types of cancer.
More About Lutetium Lu 177-Dotatate
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine Tumors
Targeted Therapy to Treat Cancer
Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age
Clinical Trials Accepting Patients
Find Clinical Trials for Lutetium Lu 177 Dotatate – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
